Clinical Neuroscience & Neurological Research International Journal
ISSN: 2689-6001

Academic Strive
Researcher's perception is our reality

Review Article *Volume 6 Issue 1*

The Role of Post-Translational Modifications in Synaptic Function and Neurological Disorders

Almoeiz Y Hammad*

Department of Biochemistry, Omdurman Ahlia University, Sudan

***Corresponding author:** Almoiez Y Hammed, Department of Biochemistry, Faculty of Medicine, Omdurman Ahlia University, Sudan, Email: almoeiz7@gmail.com

Received Date: December 09, 2024; **Published Date:** January 02, 2025

Abstract

Post-translational modifications (PTMs) are crucial regulators of protein function, influencing nearly every aspect of cellular behavior, from signaling to protein degradation. In the nervous system, PTMs play a vital role in synaptic function, affecting processes such as neurotransmission, synaptic plasticity, and neuronal survival. These modifications, including phosphorylation, acetylation, ubiquitination, methylation, and glycosylation, are essential for the modulation of synaptic proteins involved in neurotransmitter release, receptor function, and memory formation. Dysregulation of PTMs can lead to aberrant synaptic activity and contribute to the pathophysiology of various neurological disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), and schizophrenia (SCZ). This review discusses the various PTMs involved in synaptic function, their impact on neuronal signaling, and their role in the development of neurological diseases, with an emphasis on potential therapeutic approaches.

Keywords: Acetylation; Alzheimer's Disease; Neurotransmission; Post-Translational Modifications; Synaptic Function; Phosphorylation

Abbreviations

PTMs: Post-Translational Modifications; AD: Alzheimer's Disease; PD: Parkinson's Disease; SCZ: Schizophrenia; CNS: Central Nervous System; LTP: Long-Term Potentiation; LTD: Long-Term Depression; PSD: Postsynaptic Density; UPS: Ubiquitin-Proteasome System; PD: Parkinson's Disease.

Introduction

The central nervous system (CNS) relies on complex signaling networks that regulate the function and plasticity of synapses-the communication points between neurons. These networks involve a vast array of synaptic proteins, whose activities are tightly controlled through various mechanisms, with one of the most significant being post-translational modifications (PTMs). PTMs are chemical alterations that occur after protein synthesis, which can regulate protein function, localization, stability, and interactions [1,2]. Common PTMs in the nervous system include phosphorylation, acetylation, ubiquitination, methylation, and glycosylation, which modulate critical neuronal processes such as synaptic vesicle release, receptor trafficking, and synaptic strength [3,4]. The dynamic regulation of PTMs in neurons is essential for synaptic plasticity, the process by which synapses adapt to changes in activity, thought to underlie learning and

memory [5,6]. Disruptions in PTM signaling, however, can lead to synaptic dysfunction, which is a hallmark of many neurological diseases [7]. This review explores the role of PTMs in synaptic function and their dysregulation in the pathogenesis of neurodegenerative and neuropsychiatric disorders [8].

Types of Post-Translational Modifications in the Nervous System

Phosphorylation: Phosphorylation is one of the most studied and versatile PTMs, involving the addition of phosphate groups to the hydroxyl groups of serine, threonine, or tyrosine residues. This process is catalyzed by protein kinases and reversed by phosphatases. Phosphorylation regulates protein conformation, stability, and interactions, influencing a wide range of synaptic functions, including neurotransmitter release, receptor function, and synaptic plasticity. For example, the phosphorylation of synaptic proteins such as synapsins modulates synaptic vesicle mobilization and neurotransmitter release. Additionally, phosphorylation of glutamate receptors, particularly NMDA receptors, is crucial for synaptic plasticity mechanisms like long-term potentiation (LTP) and long-term depression (LTD), which are essential for learning and memory formation. Moreover, the phosphorylation of scaffolding proteins at the postsynaptic density (PSD) regulates receptor trafficking and synapse remodeling. In neurological diseases, improper phosphorylation can lead to aberrant protein function. In Alzheimer's disease (AD), for example, tau, a microtubule-associated protein, becomes hyperphosphorylated, forming neurofibrillary tangles-hallmarks of the disease. This hyperphosphorylation impairs tau's role in stabilizing microtubules and disrupts axonal transport, leading to synaptic dysfunction and neuronal loss [9].

Acetylation: Acetylation involves the addition of an acetyl group to the amino group of lysine residues on proteins. This PTM influences protein stability, function, and interactions. In the nervous system, acetylation plays a role in both transcriptional regulation and synaptic signaling. Acetylation of histones is a well-known mechanism that regulates gene expression by altering chromatin structure, making DNA more accessible for transcription.

Non-histone proteins, such as tubulin and α-synuclein, can also undergo acetylation. For example, acetylation of α-tubulin affects microtubule dynamics and synaptic vesicle transport. Additionally, acetylation of α-synuclein, a protein implicated in Parkinson's disease (PD), modulates its aggregation propensity and may contribute to the formation of Lewy bodies. In AD, acetylation of amyloid-β peptides has been shown to enhance their aggregation and toxicity, contributing to synaptic dysfunction [10].

In neurodegenerative diseases like AD and PD, decreased acetylation of histones has been linked to dysregulated gene expression and impaired synaptic plasticity. Targeting acetylation pathways may offer therapeutic potential for these diseases [11].

Ubiquitination: Ubiquitination is the attachment of ubiquitin, a small protein, to lysine residues of target proteins. This PTM is primarily known for marking proteins for degradation by the proteasome but also plays roles in regulating protein localization and interactions. In neurons, ubiquitination is involved in synaptic plasticity by regulating the turnover of neurotransmitter receptors, such as AMPA and NMDA receptors, and by controlling synaptic vesicle recycling.

For instance, ubiquitination of synaptic proteins like the AMPA receptor can regulate its endocytosis and recycling, processes central to LTP and LTD. Dysregulation of ubiquitination has been implicated in several neurological disorders. In AD, for example, defects in the ubiquitin-proteasome system (UPS) impair the clearance of misfolded proteins, leading to the accumulation of toxic aggregates, including amyloid-β and tau [12].

In Parkinson's disease, mutations in genes encoding components of the UPS, such as parkin, lead to the accumulation of damaged proteins and neuronal degeneration. Maintaining proper UPS function is crucial for synaptic health [13].

Methylation: Methylation refers to the addition of a methyl group to the nitrogen atom of lysine or arginine residues on proteins. This PTM can alter protein conformation and modulate protein-protein interactions. In neurons, methylation regulates gene expression and synaptic signaling by affecting chromatin structure and the activity of transcription factors.

Histone methylation is particularly important for regulating genes involved in synaptic plasticity. For example, methylation of histones at specific loci can promote or repress the expression of genes critical for synapse formation and function. In neuropsychiatric disorders such as schizophrenia, altered DNA methylation patterns have been observed in genes that regulate synaptic signaling, suggesting that epigenetic modifications play a role in disease pathogenesis [14].

Methylation of non-histone proteins, such as the glutamate receptor subunit GluR1, has also been linked to synaptic plasticity and memory formation. Alterations in protein methylation could contribute to cognitive impairments in

both neurodevelopmental and neurodegenerative disorders [15].

Glycosylation and Other PTMs: Glycosylation is the addition of sugar moieties to proteins, affecting protein folding, stability, and interactions. In the nervous system, glycosylation regulates synaptic vesicle function and receptor trafficking. For example, the glycosylation of synaptic proteins like synaptotagmin plays a role in neurotransmitter release. While less studied than other PTMs, glycosylation is emerging as an important regulator of synaptic function and plasticity.

Other PTMs, such as sumoylation (the attachment of small ubiquitin-like modifiers to proteins), can also influence synaptic activity by modulating protein interactions and localization. Sumoylation has been shown to regulate the activity of transcription factors involved in synaptic plasticity [16].

Dysregulation of PTMs in Neurological Disorders: Impaired regulation of PTMs can lead to synaptic dysfunction, a key feature of several neurological disorders.

Alzheimer's Disease (AD): In AD, the dysregulation of PTMs-particularly phosphorylation, acetylation, and ubiquitination-plays a central role in disease progression. Hyperphosphorylation of tau leads to the formation of neurofibrillary tangles, impairing axonal transport and disrupting synaptic function. Acetylation of amyloid-β and tau peptides promotes their aggregation and toxicity, further contributing to synaptic dysfunction.

Moreover, impaired ubiquitination and proteasomal degradation of misfolded proteins lead to the accumulation of toxic aggregates, further disrupting synaptic function. Restoring the balance of PTMs, such as through the use of histone deacetylase inhibitors, has shown promise in preclinical models of AD, highlighting the therapeutic potential of targeting PTM pathways [17].

Parkinson's Disease (PD): In PD, α-synuclein, a protein involved in synaptic vesicle function, undergoes various PTMs, including phosphorylation, acetylation, and ubiquitination. Phosphorylation of α-synuclein promotes its aggregation, while acetylation affects its oligomerization and interaction with synaptic vesicles. Ubiquitination of α-synuclein is critical for its clearance by the proteasome, and defects in this process contribute to the accumulation of toxic aggregates in neurons.

Furthermore, mutations in genes encoding ubiquitin ligases, such as parkin, impair protein degradation pathways and contribute to the pathogenesis of PD. Targeting PTM pathways involved in α-synuclein aggregation and clearance offers a promising therapeutic strategy [18].

Schizophrenia (SCZ): In schizophrenia, alterations in PTMs-particularly methylation and phosphorylation-have been implicated in the dysregulation of synaptic signaling. DNA methylation changes in genes regulating synaptic plasticity, such as the NMDA receptor subunit NR1, have been associated with cognitive impairments in schizophrenia. Additionally, altered phosphorylation of dopamine receptors and synaptic proteins contributes to impaired neurotransmission and synaptic dysfunction.

Emerging evidence suggests that targeting epigenetic modifications, including DNA and histone methylation, could offer new therapeutic approaches for managing schizophrenia [19].

Conclusion

Post-translational modifications are essential regulators of synaptic function, and their dysregulation is a key factor in the pathogenesis of many neurological disorders. By influencing protein activity, stability, and interactions, PTMs regulate neurotransmitter release, receptor signaling, and synaptic plasticity, all of which are crucial for normal brain function. Understanding the molecular mechanisms underlying PTM regulation in neurons will provide valuable insights into the development of therapeutic strategies for diseases like Alzheimer's, Parkinson's, and schizophrenia.

References

1. Rosenthal KJ, Gordan JD, Scott JD (2024) Protein kinase A and local signaling in cancer. Biochemical Journal 481(22): 1659-1677.

2. Hobble HV, Schaner TCE (2024) Intrafamily heterooligomerization as an emerging mechanism of methyltransferase regulation. Epigenetics & Chromatin 17(1): 5.

3. Baek SH, Kim YS, Lee YS (2018) Acetylation of synaptic vesicle proteins regulates neurotransmitter release. Nat Commun 9(1): 575.

4. Pakdaman Y (2021) Dysfunction of the protein quality control system in neurodegeneration: A study of the co-chaperone and ubiquitin ligase CHIP in vitro and in zebrafish. Bergen Open Research Archive, Norway.

5. Pan Y, He X, Li C, Li Y, Li W, et al. (2021) Neuronal activity recruits the CRTC1/CREB axis to drive transcription-dependent autophagy for maintaining late-phase LTD. Cell Reports 36(3): 109398.

6. Pazarcı P (2024) Molecular basis of learning and memory. Scientific Reports in Medicine. 1(1): 29-37.

7. Synowitz M (2014) Glia in synaptic function and dysfunction. J Neurosci Res 42(1): 1-16.

8. Mukherjee U, Abel T (2024) Molecular Intersection of Activity-Dependent Gene Expression and Behavior: The Transcriptomic Signature of Long-Term Memory. In: Transcriptional Regulation by Neuronal Activity: To the Nucleus and Back, Cham: Springer Nature Switzerland pp: 433-468.

9. Nasb M, Tao W, Chen N (2024) Alzheimer's disease puzzle: delving into pathogenesis hypotheses. Aging and Disease 15(1): 43.

10. Kim H, Lee Y, Kim Y (2014) Acetylation of α-synuclein and its effects on aggregation in Parkinson's disease. Neurobiol Aging 35(6): 1565-1573.

11. He Y, Wu Y, Zhang D (2020) Acetylation of histones in Alzheimer's disease: A promising therapeutic target. Aging Cell 19(9): e13118.

12. Ciechanover A, Kwon YT (2017) Degradation of misfolded proteins in neurodegenerative diseases: Mechanisms and therapeutic strategies. Exp Mol Med 49(10): e366.

13. Tait S, Lee C, Koh JY (2015) Ubiquitin-proteasome system in Parkinson's disease: Lessons from genetics. Prog Neurobiol 131: 90-114.

14. Li J, Zhang Z (2020) Methylation of synaptic genes in neurodevelopmental and neuropsychiatric disorders. Neuropsychopharmacology 45(5): 945-957.

15. Zhang J, Zhao J, Ma Z (2020) Methylation of GluR1 in synaptic plasticity. Front Mol Neurosci 13: 202.

16. Marks F, Klingmüller U, Müller-Decker K (2017) Cellular signal processing: an introduction to the molecular mechanisms of signal transduction. Garland Science.

17. Sugars KL, Rubinsztein DC (2003) Histone deacetylase inhibitors as therapeutic agents in neurodegenerative disease. Nat Rev Neurosci 4(11): 1-14.

18. Mejía CA (2024) Therapeutic Exercise for Parkinson's Disease and Related Disorders: A Comprehensive Clinical Strategy for Preventing and Reversing Neurodegeneration. Springer Nature.

19. Lattari G, Souza-Moreira L, Alvarenga W (2019) Epigenetic regulation in schizophrenia: The role of DNA methylation. Front Psychiatry 10: 694.